Albireo Pharma (ALBO) Stock Price, News & Analysis

Company Overview

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Key Stats

• Today's Range: N/A
• 50-Day Range: $43.50 to $44.95
• 52-Week Range: N/A
• Volume: 1.24 million shs
• Average Volume: 704,539 shs
• Market Capitalization: $913.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ALBO Stock Analysis - Frequently Asked Questions

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $3.28. The biopharmaceutical company earned $3.66 million during the quarter, compared to analyst estimates of $22.33 million. Albireo Pharma had a negative trailing twelve-month return on equity of 97.13% and a negative net margin of 228.51%.

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Albireo Pharma investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Gilead Sciences (GILD), Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Corning (GLW) and Devon Energy (DVN).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 4/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ALBO
• CIK: 1322505
• Web: www.albireopharma.com
• Phone: (857) 254-5555
• Fax: 203-796-5001
• Employees: 130
• Year Founded: 2003

Profitability

• EPS (Most Recent Fiscal Year): ($6.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-34,030,000.00
• Net Margins: -228.51%
• Pretax Margin: -235.11%
• Return on Equity: -97.13%
• Return on Assets: -46.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.32
• Quick Ratio: 6.23

Sales & Book Value

• Annual Sales: $40.58 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.11 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 20,700,000
• Free Float: 19,273,000
• Market Cap: $913.91 million
• Optionable: Optionable
• Beta: 1.03